Many pharmaceuticals work by targeting what are known as ”G-protein-coupled receptors”. In a new study, scientists describe how they have been able to predict how special molecules that can be used in new immunotherapy against cancer bind to these receptors. The researchers’ calculation methods are a vital contribution to future structure-based drug design.
